Commenting on media reports on the imminent approval of its Alzheimer's disease (AD) drug lecanemab in the UK, BioArctic AB (BRCTF) said, "BioArctic has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors."
In 2007, Eisai secured global rights from BioArctic to study, develop, manufacture and market lecanemab for the treatment of AD. Later, Eisai and Biogen jointly developed the drug under the collaboration agreement signed in 2014.
Results from the Phase 3 study showed that the treatment with lecanemab slowed cognitive decline by 27 percent in AD patients.
Lecanemab, marketed as leqembi is already approved in countries including the U.S., Japan, and China for the treatment of AD.
For comments and feedback: editorial@rttnews.com